Literature DB >> 28927061

5FU resistance caused by reduced fluoro-deoxyuridine monophosphate and its reversal using deoxyuridine.

Ryutaro Mori1, Manabu Futamura1, Toshiyuki Tanahashi1, Yoshihiro Tanaka1, Nobuhisha Matsuhashi1, Kazuya Yamaguchi1, Kazuhiro Yoshida1.   

Abstract

The mechanism of 5-fluorouracil (5FU) resistance was investigated, focusing on the level of thymidylate synthase (TS) ternary complex formed with fluoro-deoxyuridine monophosphate (FdUMP). MKN45 and 5FU-resistant MKN45/F2R cells were treated with 5FU and fluoro-deoxyuridine (FdU) in combination with deoxyuridine (dU) and thymidine (dT). Subsequently, the levels of ternary complex were determined by western blotting and the cell viability was calculated using an MTT assay. MKN45/F2R cells exhibited 5FU resistance (56.2-fold relative to MKN45 cells), and demonstrated decreased orotate phosphoribosyltransferase (OPRT) and increased TS levels, requiring a higher concentration of 5FU to induce ternary complex formation than MKN45 cells. Following transfection of small interfering RNA against OPRT, MKN45 exhibited increased resistance to 5FU and decreased ternary complex formation subsequent to treatment with 5FU, indicating that decreased OPRT led to increased 5FU resistance. However, MKN45/F2R also exhibited resistance to FdU, which can be converted to FdUMP without OPRT, and there was decreased ternary complex formation after treatment with FdU, indicating that the 5FU-resistant cells had the ability to decrease intracellular FdUMP. The addition of dU and thymidine dT to 5FU promoted the formation of ternary complexes and reversed 5FU resistance in MKN45/F2R cells, although dT inhibited the efficacy of raltitrexed (another TS inhibitor). These results suggested that 5FU-resistant cells had the ability to reduce intracellular FdUMP irrespective of decreased OPRT, which led to resistance to 5FU. This resistance was then inhibited by treatment with dT or dU.

Entities:  

Keywords:  5FU; drug resistance; fluorodeoxyuridylate; stomach neoplasms

Year:  2017        PMID: 28927061      PMCID: PMC5588021          DOI: 10.3892/ol.2017.6512

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

1.  The molecular perspective: methotrexate.

Authors:  D S Goodsell
Journal:  Oncologist       Date:  1999

2.  In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines, and their nucleosides and deoxynucleosides.

Authors:  G Santelli; F Valeriote
Journal:  J Natl Cancer Inst       Date:  1980-01       Impact factor: 13.506

3.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

4.  Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106.

Authors:  J C Drake; C J Allegra; P G Johnston
Journal:  Anticancer Drugs       Date:  1993-08       Impact factor: 2.248

5.  Fluorodeoxyuridine with continuous leucovorin infusion. A phase II clinical trial in patients with metastatic colorectal cancer.

Authors:  R D Levin; J H Gordon
Journal:  Cancer       Date:  1993-11-15       Impact factor: 6.860

6.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes.

Authors:  G J Peters; E Laurensse; A Leyva; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

7.  Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion.

Authors:  C E Myers; R C Young; B A Chabner
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

8.  Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.

Authors:  G Francini; R Petrioli; L Lorenzini; S Mancini; S Armenio; G Tanzini; S Marsili; A Aquino; G Marzocca; S Civitelli
Journal:  Gastroenterology       Date:  1994-04       Impact factor: 22.682

9.  Thymidine rescue of high-dose methotrexate in humans.

Authors:  S B Howell; W D Ensminger; A Krishan; E Frei
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

10.  A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.

Authors:  Kalpesh Patel; Sashidhar R Yerram; Nilofer A Azad; Scott E Kern
Journal:  Oncotarget       Date:  2012-07
View more
  5 in total

1.  The mechanism underlying resistance to 5-fluorouracil and its reversal by the inhibition of thymidine phosphorylase in breast cancer cells.

Authors:  Ryutaro Mori; Junko Ukai; Yoshihisa Tokumaru; Yoshimi Niwa; Manabu Futamura
Journal:  Oncol Lett       Date:  2022-07-15       Impact factor: 3.111

2.  Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation.

Authors:  Anmada Nayak; Sarita Das; Deepika Nayak; Chinmayee Sethy; Satya Narayan; Chanakya Nath Kundu
Journal:  Cell Oncol (Dordr)       Date:  2019-01-03       Impact factor: 6.730

3.  Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines.

Authors:  Tomonari Suetsugu; Ryutaro Mori; Manabu Futamura; Masahiro Fukada; Hideharu Tanaka; Itaru Yasufuku; Yuta Sato; Yoshinori Iwata; Takeharu Imai; Hisashi Imai; Yoshihiro Tanaka; Naoki Okumura; Nobuhisa Matsuhashi; Takao Takahashi; Kazuhiro Yoshida
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

4.  Trapping of 5-Fluorodeoxyuridine Monophosphate by Thymidylate Synthase Confers Resistance to 5-Fluorouracil.

Authors:  Chinatsu Kurasaka; Nana Nishizawa; Yoko Ogino; Akira Sato
Journal:  ACS Omega       Date:  2022-02-09

5.  Molecular Mechanisms and Tumor Biological Aspects of 5-Fluorouracil Resistance in HCT116 Human Colorectal Cancer Cells.

Authors:  Chinatsu Kurasaka; Yoko Ogino; Akira Sato
Journal:  Int J Mol Sci       Date:  2021-03-13       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.